Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
May 24, 2022
MINNEAPOLIS, May 23, 2022 -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing... Learn More
XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina
May 18, 2022
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2... Learn More
Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding
February 8, 2022
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding,... Learn More
Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations
December 16, 2021
Specific Biologics Inc. (“Specific”) today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an... Learn More
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
"Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael's Hospital
"Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street